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ABSTRACT (250 words) 
Objectives: As a follow-up to the CHIPS trial (Control of Hypertension In Pregnancy Study) of ‘less 
tight’ (versus ‘tight’) control of maternal blood pressure in pregnancy, CHIPS-Child investigated 
potential developmental programming of maternal blood pressure control in pregnancy, by 
examining measures of postnatal growth rate and hypothalamic-pituitary adrenal axis activation.  
Methods: CHIPS follow-up was extended to 12±2 months corrected post-gestational age for 
anthropometry (weight, length, head/waist circumference). For eligible children with consent for 
a study visit, we collected biological samples (hair/buccal samples) to evaluate hypothalamic-
pituitary adrenal axis function (hair cortisol levels) and epigenetic change (DNA methylation 
analysis of buccal cells). The primary outcome was ‘change in z-score for weight’ between birth 
and 12±2mos. Secondary outcomes were hair cortisol and genome-wide DNA methylation status.  
Results: Of 682 eligible babies, 182 (26.7%) were lost to follow-up, 83 (12.2%) declined, 3 (0.4%) 
agreed only to ongoing contact, and 414 (60.7%) consented. 372/414 (89.9%) had weight 
measured at 12mos. In ‘less tight’ (vs. ‘tight’) control, the primary outcome was similar [-0.26 (-
0.53, +0.01); p=0.14, padjusted=0.06]; median (95% confidence interval) hair cortisol (N=35 samples) 
was lower [-496 (-892, -100) ng/g; p=0.02], and buccal swab DNA methylation (N=16 samples) was 
similar. No differences in growth rate could be demonstrated up to 5 years.   
Conclusions: Results demonstrate no compelling evidence for developmental programming of 
growth or the HPA axis. Clinicians should look to the clinical findings of CHIPS to guide practice. 
Researchers should seek to replicate these findings and extend outcomes to paediatric blood 
pressure and neurodevelopment.  
 
Key Words: 
DOHaD, birthweight, hypertension, pregnancy, growth, development, plasticity 
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INTRODUCTION 
The Developmental Origins of Health and Disease (DOHaD) concept refers to the process by which 
an exposure at a specific time during fetal or early infant development may have long-lasting or 
persistent effects on tissue structure or function after birth [1,2,3]. According to the DOHaD 
concept, the fetus will respond to prenatal cues and adapt to its environment, resulting in 
physiological changes to the phenotype of the fetus [3,4]. These changes are believed to facilitate 
survival of the child to reproductive age, known as Darwinian Fitness [5]. However, these changes 
can predispose a child to be mismatched to the environment it finds itself in as an adult, which 
can lead to the development of non-communicable diseases (NCD), such as cardiovascular disease 
and diabetes [5,6,7]. For example, there is strong evidence that fetal under-nutrition is associated 
with adult cardiovascular disease, and that the heightened risk is evident across the spectrum of 
normal birthweight [8,9,10].  
 
Epigenetics (the study of how the epigenome – which regulates gene expression – is affected by 
environmental factors) is the current concept to explain how exposures during early human 
development may be linked with childhood or adult outcomes. Epigenetic changes in humans 
have been shown to be reversible during a critical time frame of developmental plasticity [5]; 
however, these changes can also predispose cells to future malfunction and possible disease 
[11,12]. Epigenetic changes have been reported following exposures at specific points in human 
fetal development (e.g., conception in vitro) [13] and after prolonged exposure during human 
pregnancy (e.g, smoking, famine/nutrition, maternal overweight) [14,15,16]. Animal and human 
studies have shown that environmental effects (e.g., nutritional cues, maternal behaviour) on the 
fetal and newborn epigenome may be sustained as far as weaning and into early childhood 
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[17,18,3], leading to descriptions of the epigenome as the ‘archive’ of the prenatal environment 
[19]. 
 
A ‘life course’ approach to NCD prevention, from pre-conception, through pregnancy, early years 
of life, and beyond has been advocated by the United Nations and emphasized by the Sustainable 
Development Goals, known as ‘SDGs’ [3,5,6,11]. Public Health policies globally should consider 
human development as a crucial factor in diminishing the risk of NCDs in all societies. However, a 
major challenge for human studies of DOHaD is demonstration of exposure-outcome 
relationships. Although one can manipulate the maternal or fetal environment to some extent, 
clearly, it is neither ethical nor feasible in humans to intentionally deprive the mother or fetus of 
nutrition, or expose the mother or infant to prolonged stress. Yet, whether developmental 
programming occurs in response to interventions in pregnancy is of vital importance to maternity 
care providers. To date, human studies have taken epidemiological approaches (mostly 
retrospective and cross-sectional) and drawn inference (but not causation) from statistical 
associations of variables and outcomes [20].  
 
The CHIPS Trial (Control of Hypertension In Pregnancy Study, NCT01192412) was a rigorous 
randomised controlled trial of BP control during pregnancy, designed to keep mothers safe and 
optimise outcomes for babies [21]. CHIPS tested the hypothesis that ‘less tight’ (vs. ‘tight’) BP 
control would improve fetal growth (which it may have) and through that, reduce the risk of 
death or illness for the baby (which it did not). This hypothesis was based on the premise that 
‘less tight’ (vs. ‘tight’) BP control would be less likely to decrease uteroplacental perfusion and 
fetal nutrition, leading to better fetal and newborn outcomes - an argument strengthened by a 
meta-regression analysis that associated greater antihypertensive-induced falls in mean arterial 
pressure with decreased fetal growth velocity.40,41 
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CHIPS recruited 987 women in 94 centres internationally. Women randomised to ‘less tight’ 
control (target diastolic BP 100mmHg), compared with ‘tight’ control (target diastolic BP 
85mmHg), of maternal BP had higher BP (by 5.8/4.6mmHg) and similar rates of serious 
complications for the baby (primary outcome) or the mother (secondary outcome). ‘Less tight’ 
(vs. ‘tight’) control was associated with an increase in other risks for the mother (i.e., more severe 
maternal hypertension, low platelet counts, and elevated liver enzymes). Although in the ‘less 
tight’ (vs. ‘tight’) control group fewer babies may have been born with a birth weight <10th 
centile’ (not significant), more babies may have been born with preterm birth (also not 
significant).  
 
CHIPS-Child was a separate study that extended follow-up in CHIPS to examine potential 
developmental programming associated with maternal BP control, separate from genetic and 
environmental factors such as prenatal nutrition. Follow-up of the babies was extended to 
measure growth, hypothalamic-pituitary-adrenal (HPA) axis function, and epigenetic change at 
age 12 months. CHIPS-Child tested the hypothesis that babies in the ‘less tight’ control group 
would have had: (i) better antenatal nutrition and a slower rate of postnatal growth compared 
with babies in the ‘tight‘ control who may have exhibited accelerated postnatal ‘catch-up’ growth 
(our primary measure of developmental programming) in the postnatal period 
[10,12,22,23,24,25] ; (ii) less HPA axis activation; and (iii) changes in DNA methylation that may 
mediate these findings.    
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METHODS 
CHIPS sites that were interested in participating in CHIPS-Child extended CHIPS follow-up from six 
weeks postpartum until either September 2015 or when the child was five years of age, whichever 
was earlier. CHIPS-Child required specific ethics approval, in addition to CHIPS, at the central co-
ordinating centre, University of British Columbia (Oct 13, 2011, H08-00882), and at each study 
site.  
 
Site co-ordinators contacted (by phone, email, or in person at hospital visits) CHIPS participants 
who had: (i) experienced a live birth without neonatal death in CHIPS, and (ii) not withdrawn their 
consent or been lost to follow-up antepartum or postpartum during CHIPS. All participants gave 
fully informed written consent to participate in CHIPS-Child.  
 
The type of potential CHIPS-Child participation depended on the age of the child at study contact 
and the interest of the parent/guardian, as follows.  
1) When children were ≤14 months corrected post-gestational age at the time of study contact 
with the parent, s/he was approached for consent to ‘FULL’ participation of the child. This 
involved a face-to-face study visit for the child at 12 ± 2 months corrected post-gestational age. 
Anthropomorphic measurements were taken, biological samples collected, and a maternal 
questionnaire completed (see below). The anthropomorphic measurements were weight, length, 
and waist and head circumference (see below). Hair samples were obtained for evaluation of 
cortisol as a measure of HPA axis activation. Buccal swabs were taken for extraction of DNA and 
epigenetic testing by DNA methylation. (For details of the hair and buccal swab collection, see 
Appendix S1). The maternal questionnaire covered details of maternal education, post-
randomisation practices not collected in CHIPS (such as exposure to environmental smoking), and 
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infant feeding practices.  
2) When children were ≥15 months at first study contact, or if the family declined FULL 
participation, the parent/guardian was approached for consent to ‘LIMITED’ participation of the 
child. This involved giving consent for the site co-ordinator to obtain (from family doctors, 
paediatricians, or health clinics, as relevant) the child’s weight and length measurements taken 
during routine clinical visits at 12 ± 2 months corrected post-gestational age. At 28 months into 
the study, a protocol amendment was made so that the parent/guardian was also asked for their 
consent to complete the maternal questionnaire by phone; those parents/guardians who had 
already consented to LIMITED participation had to re-consent prior to questionnaire completion. 
No biological samples were collected from LIMITED participants as they were not physically seen.  
3) When the parent/guardian declined both FULL and LIMITED participation for their child, the 
parent/guardian was, as for all participants, approached for consent to ‘maintenance of contact’ 
every four months throughout the study period (i.e., Oct 2011-Sept 2015) or until the child turned 
5 years of age. This maintenance of contact was designed to confirm contact details and leave 
open the option of further follow-up.  
 
At the time of receipt of written consent to CHIPS-Child, all families had been sent a CHIPS-Child 
tape measure, wall-mounted height chart, and instructions for how to take each of the 
measurements, with particular attention paid to the correct placement of the wall chart on the 
wall, and tape measure on the child for measurement of waist circumference. Thus, on the 
approximate date of the child’s birthday (corrected post gestational age ± 2 months), families 
were sent a stamped postcard with a request for the child’s weight, height, and waist 
circumference measurements to be recorded and returned to the study co-ordinator.  
Our primary outcome was ‘change in z-score for weight’ between birth and 12 months corrected 
post-gestational age, using the Fenton et al 2013 calculator [26] for weight at birth (collected in 
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CHIPS) and the World Health Organization (WHO) calculator [27] for weight at 12 ± 2 months. Our 
secondary outcomes were hair cortisol levels and genome-wide DNA methylation status. Other 
outcomes included between-group differences in other anthropometry measures at 12 ± 2 
months and annually, from 2-5 years.  
 
Statistics 
At participating sites, comparability of our follow-up population was assessed by comparing 
maternal pre-randomisation [i.e., centre, type of hypertension, type of antihypertensive, and 
maternal body mass index (BMI)] and livebirth characteristics (i.e., gestational age at delivery, 
birth weight, and high level neonatal care for >48hr) between children who were followed-up and 
those who were not. A similar analysis was then undertaken for children who were followed up, 
according to whether their mothers had been in ‘less tight’ vs. ‘tight’ control groups in CHIPS. 
Fisher’s Exact, Student’s t-, or Mann-Whitney U tests were used, as applicable, for categorical or 
continuous variables. A p value <0.05 was considered statistically significant. The unit of analysis 
throughout was the woman (pregnancy). There were no multiple pregnancies in CHIPS. 
The primary outcome was compared between ‘less tight’ and ‘tight’ control groups using linear 
regression, adjusted for maternal pre-randomisation factors (hypertension type and centre, 
antihypertensive type, BMI and any between-group differences at baseline among babies 
followed-up) (two-tailed p<0.05). In an exploratory analyses (because differences could have 
resulted, at least in part, by the intervention itself), adjustment was made for post-randomisation 
antenatal or postnatal influences on the baby’s postnatal weight gain (most notably nutrition) 
that may have resulted in between-group differences: post-randomisation antenatal maternal 
smoking or intake of folate-containing vitamins, socioeconomic status (as reflected by country of 
origin and maternal years of education), livebirth characteristics (as listed above), and measures 
of early postnatal nutrition (i.e., breastfeeding to any extent, and the presence of health or dental 
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problems that may have affected eating). With a two-tailed alpha of 0.05 and SD of the z-score of 
1 (by definition), we calculated that we would have >80% power to detect a clinically relevant 
between-group difference in ‘change in z-score for weight’ of 0.25 with follow-up as low as 
253/group.  
 
The rate of ongoing growth (in terms of weight), was assessed annually following an age of 12±2 
months, and compared between groups by mixed effects linear regression, with centre and 
subject as a random effect, and adjustment for maternal pre-randomisation factors listed above 
for analysis of the primary outcome. A mixed effects approach was taken to account for the 
inclusion of different children at different time points, based on their age at follow-up contact in 
CHIPS-Child, and the maximal age that they could reach when the study ended in September 2015 
(which depended on whether they had been recruited earlier or later in the course of the CHIPS 
Trial, 2009-12). For the year 2-5 growth measurements, we included only babies whose growth 
measurements were taken by parents on or after recruitment to CHIPS-Child, as parents needed 
to receive the study materials in order to take accurate measurements.  
 
Hair cortisol was measured using a salivary enzyme immunoassay kit. Hair cortisol, a continuous 
variable, was compared between groups using multiple linear (least-squares) regression analysis, 
adjusted for type of hypertension, maternal BMI, and duration of participation in CHIPS.  
DNA methylation status (from buccal swab DNA) was assessed genome-wide, between ‘less tight’ 
and ‘tight’ control groups, using a false discovery rate (FDR) calculation based on ‘Significance 
Analysis of Microarrays’ [28]. This method assigns a score to each DNA site evaluated on the basis 
of change in measurement relative to the SD of repeated measurements. The technique is more 
appropriate to address the multiple-test problem present in microarray data than is using the 
Bonferroni correction. The FDR threshold is determined from the observed distribution of p-
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values (i.e., the number of results with a specific p is calculated relative to those expected by 
chance). Differentially methylated sites were prioritised based on: (i) a FDR <10% (meaning that 
>90% of sites identified as significant are likely true findings), (ii) a between-group difference in 
means >10% (as a measure a biologically significant difference), and (iii) the site(s) having a 
potential role in growth/HPA axis activation. Any candidate altered sites were to be verified using 
pyrosequencing.  
 
‘Other’ outcomes were compared between groups using a two-sample t-test for continuous 
outcomes, and chi-square or Fisher’s Exact test (as appropriate) for categorical outcomes.  
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RESULTS 
Participants 
Fifty-nine of the 94 CHIPS sites (62.8%), with 754/987 CHIPS participants (76.4%), chose to 
participate in CHIPS-Child. Figure 1 describes the flow of these women through CHIPS into CHIPS-
Child, resulting in 682 babies who were potentially eligible for CHIPS-Child in ‘less tight’ (N=346) 
and ‘tight’ control (N=336) groups. 182 (102 vs. 80, 26.7% overall) CHIPS-Child participants were 
lost to follow-up, leaving 500 (244/346, 70.5% in ‘less tight’ and 256/336, 76.2% in ‘tight’ control, 
p=0.14) who were successfully contacted and 417 (198/244, 81.1% in ‘less tight’ and 219/256, 
85.5% in ‘tight’ control, p=0.186) who consented to participation.  
 
Table 1 shows that CHIPS participants who were followed-up, compared with those who were 
not, were more likely to be from high perinatal mortality ratio (PMR) countries, especially South 
America. However, most subjects still came from North America (32.9%) and the UK/Europe 
(44.1%). 
 
The nature of potential study participation depended on the age of the child at first study contact 
which was almost always with the mother (240, 98.4% in ‘less tight’ and 253, 98.8% in ‘tight’; 
p=0.72) and at a median [IQR] corrected post-gestational age of 27.7 [18.0, 38.2] months in ‘less 
tight’ and 29.2 [20.4, 38.8] months in ‘tight’ (p=0.49). At first contact, only 92 children (47, 19.3% 
in ‘less tight’ and 45, 17.6% in ‘tight’) were actually eligible for a study visit based on a corrected 
post-gestational age of <15 months; 81 children, plus one additional child who was actually ≥15 
months at the time of contact, were invited to undertake FULL participation, of whom 45 (54.9%) 
consented (22/41, 53.7% in ‘less tight’ and 23/41, 56.1% in ‘tight’). Those who did not consent to 
FULL participation, as well as the 407 other children who were ≥15 months at the time of first 
15 
 
 
 
study contact, were all approached to undertake LIMITED participation; 369/455 (81.1%) 
consented. The remaining 3 participants (2 in ‘less tight’ and 1 in ‘tight’) consented only to 
maintenance of contact. Figure 1 summarises the nature of participation among the 500 
participants who were followed up: 83 (16.6%; 46, 18.9% in ‘less tight’ and 37, 14.5% in ‘tight’) did 
not consent to participate in any way; 45 (9.0%; 22, 9.0% in ‘less tight’ and 23, 9.0% in ‘tight’) 
consented to FULL participation; 369 (73.8%; 174, 71.3% in ‘less tight’ and 195, 76.2% in ‘tight’) to 
LIMITED participation;  3 (0.6%; 2, 0.8% in ‘less tight’ and 1, 0.4% in ‘tight’) consented to 
maintenance of contact only.  
 
Table 2 shows that of CHIPS-Child participants, babies in ‘less tight’ (vs. ‘tight’) control were more 
likely to be born at an earlier gestational age, similar to what we reported in CHIPS [13].  
 
• Postnatal growth 
Of 414 CHIPS-Child participants who consented to FULL or LIMITED participation, the infant’s 
weight was recorded for 372 (89.9%) (175/198, 88.4% in ‘less tight’ and 197/219, 90.0% in ‘tight’), 
either by the study co-ordinator at the study visit (N=45, 22 in ‘less tight’ and 23 in ‘tight’) or by 
doctors in their offices as part of routine care (N=327, 153 in ‘less tight’ and 174 in ‘tight’). Of 
these 372 measurements, 294 (79.0%) (137, 78.3% in ‘less tight’ and 157, 79.7% in ‘tight’) were 
within the 12±2 months specified in the primary outcome. Supplementary Table S2 shows that 
there was no difference in pre-randomisation maternal (or post-randomisation live birth 
characteristics) between children in ‘less tight’ vs. ‘tight’ control who had weight recorded at 12 
months (vs. those who did not).  
 
The CHIPS-Child primary outcome, change in z-score for weight between birth and 12±2 months, 
appeared to be lower in ‘less tight’ (vs. ‘tight’) control, but the result was not statistically 
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significant in analyses that were unadjusted (-0.21, 95% CI -0.48, +0.07; p=0.14) or adjusted for 
maternal pre-randomisation factors (see methods) (-0.26, 95% CI -0.53, +0.01; p=0.06). In the 
exploratory analysis that also adjusted for post-randomisation antenatal and postnatal influences 
on postnatal weight gain (see methods), a between-group difference in ‘change in z-score for 
weight’ was not evident (-0.08, 95% CI -0.34, +0.18; p=0.54). These adjustments included infant 
feeding practices for which there were no obvious differences between groups. Those practices 
were: breastfeeding at any point (117, 83.4% in ‘less tight’ vs. 121, 84.0% in ‘tight), a perception 
that the infant was not eating adequately (mean score of 7.1 ± 2.1 in ‘less tight’ and 7.3 ± 2 in 
‘tight’ on a self-rated scale of 1 to 10, with 1 being ‘poor food intake’ and 10 being ‘excellent’), or 
the presence of any medical or dental problems that could affect eating (15, 10.7% in ‘less tight’ 
vs. 16, 11.1% in ‘tight’). 
 
There was no significant difference in annual postnatal growth rate from birth to 5 years in ‘less 
tight’ (vs. ‘tight’) control, despite the impression that postnatal growth rate may be slower until 
two years and then more rapid from three years (Figure 2, Supplementary Table S3). Similar 
results were seen when growth was assessed relative to birth (Supplementary Table S4). The 
number of babies with annual weight measurements decreased over time: 129/180 (71.7%) at 2 
years, 150/300 (50.0%) at 3 years, 86/204 (42.1%) at 4 years, and 21/70 (30.0%) at 5 years of age. 
Any apparent reduction in follow-up in the ‘less tight’ (vs. ‘tight’) control over time did not reach 
statistical significance at 2 years (65/91, 71.4% vs. 64/89, 71.9%; p=0.94), 3 years (71/145, 49.0% 
vs. 79/155, 51.0%; p=0.73), 4 years (32/92, 34.8% vs. 54/112, 48.2%; p=0.05), or 5 years (5/29, 
17.2% vs. 16/41, 39.0%; p=0.05) although data were limited at this last time point. These numbers 
reflected attrition of some children and the addition of others who had their anthropometry 
taken by parents after CHIPS-Child recruitment; by September 2015 when the study ended, all 
children had turned 2 years of age (although N=133 were not recruited prior to this birthday), 
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most (N=187) had turned 3 years, many had reached 4 years (N=132) and some had reached 5 
years of age (N=59).  
 
For the ‘other’ anthropometry outcomes of length (at 12±2 mos), standing height (at 2-5 years), 
head circumference (at 12±2 mos), and waist circumference (at years 1-5), there were no 
differences between ‘less tight’ and ‘tight’ control groups (Supplementary Table S5).  
 
• Secondary outcomes: hair cortisol and DNA methylation 
Secondary outcomes were examined for the 45 children who attended a study visit as part of FULL 
participation. Hair samples were collected from 41 children (91.1%) (18/22 in ‘less tight’ and 
23/23 in ‘tight’ control). Four children in ‘less tight’ control did not have hair collected because 
the child did not have enough hair to collect, or the parent considered it culturally unacceptable 
to cut the hair, s/he did not want the sample sent overseas, or s/he did not want their child to 
participate in this part of the study (one each). 35/41 (85.4%, 15 in ‘less tight’ and 20 in ‘tight’) 
hair samples contained sufficient hair to measure cortisol. The characteristics of these children 
were not statistically different between groups (Supplementary Table S6). 
 
Median [IQR] hair cortisol was significantly lower in ‘less tight’ (vs. ‘tight’) control (261.7 [33.5, 
519.8] vs. 668.8 [316.4, 1039.9] ng/g; p=0.03), a difference that persisted following adjustment 
(see methods) (-495.82 [-891.62, -100.01]; p=0.02). The difference could not be accounted for by 
maternal adverse outcomes [i.e., no serious maternal complications, and similar rates of severe 
hypertension (6/15, 40.0% in ‘less tight’ vs. 7/20, 35.0% in ‘tight’; p=0.76) and pre-eclampsia 
(9/15, 60.0% vs. 7/20, 35.0%, respectively; p=0.14)], maternal mental health [e.g., postnatal 
antidepressant use (1/15, 6.7% vs. 1/20, 5.0%, respectively; p=1.0)], or livebirth characteristics 
[i.e., preterm birth (5/15, 33% vs. 2/20, 10.0%, respectively; p=0.11), birthweight <10th centile 
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(2/15, 13.3% vs. 0/20, respectively, ; p=0.18), or high level neonatal care for >48hr (5/15, 33% vs. 
3/20, 15.0%, respectively; p=0.25)]. The difference also remained when analyses were restricted 
to the 16 children who also had DNA samples taken (199.8 [33.5, 519.8] vs. 1174.7 [743.8, 1303.2] 
ng/g, respectively; p=0.02). There was no difference in the distribution of post-randomisation 
antihypertensive exposure among babies in ‘less tight’ (vs. ‘tight’) control: labetalol (4/15, 26.7% 
vs. 12/20, 60.0% respectively), methyldopa (6/15, 40.0% vs. 5/20, 25.0%), another 
antihypertensive (2/15, 13.3% vs. 2/20, 10.0%), or no antihypertensive (3/15, 20.0% vs.1/20,5.0%) 
(p=0.198).   
 
Buccal swab samples for DNA were collected from 41 children, but only 16 (9 in ‘less tight’ and 7 
in ‘tight’ control) had samples that passed quality control testing. 90.8% of DNA sites were 
available for analysis. The strongest associations with DNA methylation were seen with child sex, 
chip, row on the chip, and child’s age (Supplementary Figures S1a and S1b). The final model for 
differential methylation analysis was ‘allocated trial group (‘less tight’ or ‘tight’ control) + infant 
sex + infant age + chip + sample position’. No differences in DNA methylation between groups 
were identified, as indicated by the data being far below the false discovery rate of <0.05 
(Supplementary Figure S2).  
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DISCUSSION 
Summary of findings 
In this follow-up study of a large international trial of differential BP control in pregnancy, there 
was no compelling impact of ‘less tight’ (vs. ’tight’) control of hypertension on growth before birth 
(as documented in CHIPS) [21] or rate of growth after birth, as measured in CHIPS-Child. Although 
babies whose mothers received ‘less tight’ (vs. ‘tight’) control of hypertension had both apparent 
less rapid postnatal growth (as reflected by a smaller change in z-score for weight from birth) and 
less HPA axis activation (as reflected by lower hair cortisol levels) at 12±2 months of age, the 
difference in postnatal growth rate at this time did not reach statistical significance, and hair 
samples were provided by only a small subset of children (i.e., 35, 8.4% of all participants). Also, 
any apparent initial reduction in growth rate associated with ‘less tight’ (vs ’tight’) control did not 
appear to be ongoing, particularly after the age of two years, and, we could demonstrate no 
epigenetic modifications (as reflected by DNA methylation) associated with ‘less tight’ (vs. ‘tight’) 
control, even when analyses were restricted to the children who provided both hair and buccal 
swabs for DNA extraction (among whom hair cortisol was still lower in ‘less tight’ (vs. ‘tight’) 
control). Taken together, these findings suggest that if ‘less tight’ (vs. ‘tight’) control of non-severe 
hypertension in pregnancy does have developmental programming effects, they are not 
compelling, they do not remain obvious over time, and they do not seem to be mediated by 
changes in gene expression as measured by DNA methylation.  
 
How findings fit with literature 
There is strong evidence from animal experimentation and epidemiological data that prenatal 
factors can exert developmental programming effects. In relation to human health, what has been 
lacking for most exposures is experimental validation. To our knowledge, we report on the first 
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randomised trial of BP control in pregnancy (CHIPS) that has examined developmental 
programming as a follow-up outcome, as we did in CHIPS-Child.  
 
Small body size at birth is associated with lower muscle mass and higher fat to lean body mass 
ratio later in human life [30,31].  As muscle mass is critical in the storage and oxidation of glucose, 
individuals with high fat to muscle ratio have an elevated risk of insulin resistance and associated 
metabolic consequences. Consistent with this is the observation that human babies born small are 
at risk of developing cardiovascular diseases in later life [32].  
 
Whether postnatal catch-up growth is a good or bad thing following small size at birth is 
controversial. Further complicating matters is whether the timing of that catch-up growth may 
modify benefit or risk. Some literature in humans suggests that early catch-up growth is harmful; 
more rapid weight gain in the first year of life (particularly in the first three months) was 
associated with a greater percentage of body fat and reduced insulin sensitivity in young adults 
[22]. In contrast, early catch-up before age two years has been demonstrated to be beneficial; 
among babies of low birthweight, interventions aimed at increasing linear growth in the first two 
years of life led to significant gains in height and school performance [33], without a negative 
impact on glucose tolerance [34]. Also, in birth cohort studies, only more rapid growth after the 
age of two years (not before) was associated with elevated cardiovascular risk [33], including 
coronary heart disease [35] and impaired glucose tolerance [36]. These data highlight the complex 
and conflicting nature of the literature on the relationship between cardiovascular risk and 
postnatal growth rate and its timing.   
 
In CHIPS-Child, it may be reassuring that any possible accelerated postnatal growth seen among 
babies who were exposed to ‘tight’ control in utero, was evident only in the first two years of life. 
21 
 
 
 
In fact, we cannot rule out a change in the pattern of postnatal growth, and if truly different, 
whether the pattern is better or worse with regards to long-term outcomes. Different patterns of 
growth have been related to environmental influences such as infant feeding (that did not differ 
between groups in CHIPS-Child). In humans, primarily formula-fed infants, compared with 
exclusively breastfed infants, have demonstrated more rapid initial growth followed by slowed 
growth in the first year of life, with these early differences being much larger (i.e., 0.4-0.6 in z-
score) than seen in our study (approximately 0.25 in z-score) [36].  
 
It must be acknowledged that unhealthy lifestyle factors can magnify any elevated cardiovascular 
risk associated with low birthweight (or reduced growth potential in utero). In association with 
low birthweight, most of the risk of adult type 2 diabetes mellitus was accounted for by unhealthy 
lifestyle (59%) or an interaction between low birthweight and unhealthy lifestyle (18%), rather 
than low birthweight itself (22%) [37]. Conversely, following low birthweight, frequent moderate 
daily exercise (such as undertaking brisk walking three times per week) was associated with a 
reduced risk of type 2 diabetes [38]. These data are consistent with the known effect of exercise 
in improving muscular insulin sensitivity.   
 
Strengths and limitations 
Strengths of CHIPS-Child include examination of measures of developmental programming 
following antenatal measures of BP control; we are not aware of another such study. Also, the 
CHIPS Trial on which CHIPS follow-up is based, was a high-quality, large, multicentre, international 
RCT, an additional strength.  
 
An important limitation of our study is the smaller sample size (417 babies) than anticipated (506 
babies). Fewer CHIPS centres (59/94, 62.8% centres rather than 75/94, 80% anticipated) chose to 
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participate in CHIPS-Child, and our follow-up rate (73.2%) was suboptimal. Many sites’ research 
ethics boards required CHIPS-Child to be submitted as a new proposal distinct from CHIPS, such 
that by the time that local approvals were in place, only 92/500 children followed up were still 
eligible for a CHIPS-Child study visit at 12±2 mos corrected post-gestational age. This was the 
point at which biological samples were collected for hair cortisol and epigenetic analyses, further 
limiting our ability to examine these endpoints. Second, only about half of women were willing to 
bring their babies back for a face-to-face visit, because CHIPS-Child was a separate study from 
CHIPS that did not specify follow-up beyond six weeks postpartum. While we did obtain 
anthropomorphic measurements from clinical care for the purposes of the primary outcome, our 
measurements at 2-5 years of age were measured by parents, albeit with tools and instructions 
provided. Third, DNA methylation changes may have been missed because they disappeared over 
time (which would be reassuring) or they were tissue-specific and for ethical and practical 
reasons, we had access only to buccal cell DNA. Fourth, although the elevated hair cortisol values 
in the ‘tight’ control could not be explained by other confounders, other environmental factors 
that were not measured may have been causal, and the significant result may represent a type I 
error as part of many statistical comparisons. Finally, we were able to collect only basic 
information about infant feeding, with neither calorie counts nor feeding practices after infancy 
documented, and we lack information about other lifestyle factors, namely activity.  
 
Conclusions 
The results of this study suggest that any developmental programming effects as a result of 
maternal BP control during pregnancy are not convincing, do not persist over time, and appear to 
not be mediated by gene expression alterations.  For researchers, there are interesting 
observations in CHIPS-Child related to postnatal growth rate pattern and HPA axis activation that 
warrant future study, for confirmation and for association with clinical outcomes, particularly 
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paediatric BP and neurodevelopment.  For clinicians, CHIPS-Child results do not reveal compelling 
evidence for developmental programming of either postnatal growth or the HPA axis associated 
with maternal BP control during pregnancy. Clinicians should look to the clinical findings of CHIPS 
to guide clinical practice; on balance, the best approach appears to be ‘tight’ control of non-
severe pregnancy hypertension for maternal benefit, without evidence of harm to the baby in the 
short-term (as shown in CHIPS) or long-term (as demonstrated here in CHIPS-Child). Of course, for 
all individuals, healthful diet and activity throughout life are key to the avoidance of 
cardiovascular disease long-term.  
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TABLES 
Table 1: Comparability of participants followed to those not followed-up at CHIPS-Child 
participating sites   
Variable 
All CHIPS Child 
sites (n=683) 
Women NOT 
followed (n=183) 
Women followed 
(n=500) 
P* 
Maternal pre-randomisation factors    
PMR of recruiting country 
   
0.020 
Low (<10/1000 births) 602 (88.1) 170 (92.9) 432 (86.4) 
 
High (≥10/100 births ) 81 (11.9) 13 (7.1) 68 (13.6) 
 
Regions of recruiting sites 
   
0.028 
Australasia 67 (9.8) 17 (9.3) 50 (10.0) 
 
Middle East 22 (3.2) 2 (1.1) 20 (4.0) 
 
North America 225 (32.9) 74 (40.4) 151 (30.2) 
 
South America  68 (10.0) 12 (6.6) 56 (11.2) 
 
UK and Europe 301 (44.1) 78 (42.6) 223 (44.6) 
 
Type non-proteinuric hypertension 
   
0.538 
Pre-existing hypertension    508 (74.4) 133 (72.7) 375 (75.0) 
 
Gestational hypertension 175 (25.6) 50 (27.3) 125 (25.0) 
 
Antihypertensive therapy     
    Use at randomisation 370 (54.2) 101 (55.2) 269 (53.8) 0.747 
    Type at randomisation 
   
0.053 
Labetalol ± other (not methyldopa) 152 (22.3) 53 (29.0) 99 (19.8) 
 
Methyldopa ± other (not labetalol) 161 (23.6) 35 (19.1) 126 (25.2) 
 
Other 57 (8.3) 13 (7.1) 44 (8.8) 
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Variable 
All CHIPS Child 
sites (n=683) 
Women NOT 
followed (n=183) 
Women followed 
(n=500) 
P* 
None 313 (45.8) 82 (44.8) 231 (46.2) 
 
BMI (kg/m2) 
   
0.138 
< 25 161 (23.8) 36 (19.8) 125 (25.3) 
 
≥ 25 516 (76.2) 146 (80.2) 370 (74.7) 
 
Unknown 6 1 5 
 
(kg/m2) 31.2 (7.8) 31.7 (7.7) 31.0 (7.8) 0.264 
Live birth characteristics (post-randomisation)†    
Gestational age at delivery (wks)   37.3 (2.8) 37.4 (2.7) 37.3 (2.8) 0.509 
Delivery at <37 wks 201 (29.4) 52 (28.4) 149 (29.8) 0.725 
Delivery at <34 wks 78 (11.4) 19 (10.4) 59 (11.8) 0.606 
Birth weight (g) 2909.3 (820) 2875.8 (760.6) 2921.6 (841.1) 0.518 
    < 2500 g 176 (25.8) 46 (25.1) 130 (26.0) 0.819 
    < 1250 g 28 (4.1) 6 (3.3) 22 (4.4) 0.513 
    <10th centile 115 (16.8) 33 (18.0) 82 (16.4) 0.614 
    <3rd centile 26 (3.8) 5 (2.7) 21 (4.2) 0.375 
High level neonatal care for >48hr 194 (28.4) 48 (26.2) 146 (29.2) 0.446 
(N (%) and mean±SD unless otherwise stated), BMI (body mass index), PMR (perinatal mortality 
ratio) 
* The groups were compared using the Student’s t-test.  
† These characteristics were used for adjustment only in exploratory analyses.   
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Table 2: Comparability of CHIPS-Child groups according to allocated treatment in CHIPS  
Variable ‘Less tight’ control (n=244) ‘Tight’ control (n=256) P* 
Maternal pre-randomisation factors   
PMR of recruiting country 
  
0.757 
Low (<10/1000 births) 212 (86.9) 220 (85.9) 
 
High (≥10/100 births ) 32 (13.1) 36 (14.1) 
 
Region of recruiting sites 
  
0.884 
Australasia 25 (10.2) 25 (9.8) 
 
Middle East 8 (3.3) 12 (4.7) 
 
North America 71 (29.1) 80 (31.3) 
 
South America  27 (11.1) 29 (11.3) 
 
UK and Europe 113 (46.3) 110 (43.0) 
 
Type non-proteinuric hypertension 
  
0.679 
Pre-existing hypertension    185 (75.8) 190 (74.2) 
 
Gestational hypertension 59 (24.2) 66 (25.8) 
 
Antihypertensive therapy    
    Use at randomisation 127 (52.0) 142 (55.5) 0.443 
    Type at randomisation 
  
0.684 
Labetalol ± other (not methyldopa) 43 (17.6) 56 (21.9) 
 
Methyldopa ± other (not labetalol) 62 (25.4) 64 (25.0) 
 
Other 22 (9.0) 22 (8.6) 
 
None 117 (48.0) 114 (44.5) 
 
BMI (kg/m2) 
  
0.696 
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Variable ‘Less tight’ control (n=244) ‘Tight’ control (n=256) P* 
< 25 63 (26.0) 62 (24.5) 
 
≥ 25e 179 (74.0) 191 (75.5) 
 
Unknown 2 3  
(kg/m2) 30.9 (7.8) 31.0 (7.8) 0.919 
Live birth characteristics (post-randomisation)†   
Gestational age at delivery (wks)   37.0 (3.0) 37.6 (2.6) 0.019 
Delivery at <37 wks 82 (33.6) 67 (26.2) 0.069 
Delivery at <34 wks 34 (13.9) 25 (9.8) 0.149 
Birth weight (g) 2893.7 (869.3) 2948.2 (814.1) 0.469 
    < 2500 g 65 (26.6) 65 (25.4) 0.750 
    < 1250 g 13 (5.3) 9 (3.5) 0.323 
    <10th centile 34 (13.9) 48 (18.8) 0.146 
    <3rd centile 8 (3.3) 13 (5.1) 0.316 
High level neonatal care for >48hr 71 (29.1) 75 (29.3) 0.961 
(N (%) unless otherwise stated), BMI (body mass index), PMR (perinatal mortality ratio) 
* The groups were compared using the Student’s t-test 
† These characteristics were used for adjustment only in exploratory analyses. 
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FIGURE LEGENDS 
 
 
Figure 1: CHIPS Trial and CHIPS-Child study profile (for details about “rows”, see ‘flow through 
CHIPS table below footnotes) 
 
NND (neonatal death), PPQ (postpartum questionnaire) 
* These are the women who are in the CHIPS Consort Diagram and for whom we have no primary 
and secondary outcome data.  
 
 
 
Figure 2: Change in z-score for weight’ relative to birth or the year prior, until age 5 years (as 
applicable), for children in the ‘less tight’ (in black) vs. ‘tight’ (in red) control groups* 
 
*The N children evaluated at each time point relative to the year before is presented at the bottom 
of each set of box plots which represent the median, interquartile range, and outliers for each 
group. The p values for ‘less tight’ vs. ‘tight’ control comparisons are from mixed effects linear 
regression with centre and subject as random effects, and following adjustment for the maternal 
pre-randomisation factors of type of hypertension, type of antihypertensive, and maternal body 
mass index (BMI) 
 
 
 
